In contrast to the scaling back of mRNA vaccine funding in the United States, Moderna is increasing investment in Australia, establishing a regional research and manufacturing hub. This strategy leverages decades of local scientific expertise to accelerate development and delivery of new mRNA-based therapies across the Asia-Pacific region, positioning Australia as a key player in the next generation of biotechnologic innovation and regional health preparedness.